Global pharmaceutical company Eli Lilly (NYSE:LLY) reported in Q1 CY2025, with sales up 45.2% year on year to $12.73 billion.

People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

CVS pharmacy and convenience store in Baltimore, MD. August 8; 2020. Four states joined a federal lawsuit against CVS Pharmacy that claims the company caused state Medicaid programs to pay higher ...

NEW YORK — CVS ... obesity medications known as GLP-1 receptor agonists that have soared in popularity due to the amount of weight people lose while taking the injections. Coverage of these ...

Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...

They’re among the hottest-selling drugs in the country. But in Massachusetts, as elsewhere in the country, the people who would benefit most from these drugs may not be getting them, according ...

He said the deal would reduce the price that Caremark’s employer clients paid for obesity drugs by 10% to 15% compared with the previous year. Advertising “CVS Caremark was able to do what ...

The trial included 751 people from across the U.S. who were overweight or had obesity ... CVS Health said Wegovy will become the preferred option on its standard formulary, or list of covered ...

This week, CVS Health said Wegovy will become the preferred option on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be excluded. It's important to have a range of drugs ...

The data are from the first head-to-head trial comparing the wildly popular medicines, and gives Lilly more firepower as it seeks to gain wider insurance coverage in an obesity drug market ...